A Feb. 14 announcement from Bracco indicates that the recently FDA-approved, gadolinium-based contrast agent VUEWAY, also known as gadopiclenol, is officially being used for patients undergoing MR imaging.
A Feb. 14 announcement from Bracco indicates that the recently FDA-approved, gadolinium-based contrast agent VUEWAY, also known as gadopiclenol, is officially being used for patients undergoing MR imaging.